Nosis Bio announces collaboration with Cystic Fibrosis Foundation for Cell-specific Gene Therapy

BETHESDA, Md. — The Cystic Fibrosis Foundation recently agreed to provide up to $2 million to Nosis Bio to explore an alternative way to safely deliver gene therapies into the appropriate lung cells, a key challenge in cystic fibrosis. This type of therapy has the potential to treat anyone with CF, including those with rare and nonsense mutations.

Nosis Bio uses artificial intelligence (AI) to design and develop novel drug delivery molecules, called Targeted Delivery Vehicles (TDVs). For this research, Nosis intends to develop TDVs that enable the targeting of specific cells in the lung without provoking an unwanted immune response.

In July 2022, Nosis was announced as a winner of the Foundation’s inaugural “Golden Ticket” Competition, an opportunity for early-stage companies working to translate research into a potential therapy. Since then, Nosis was awarded free laboratory space and support at Bakar Labs, the incubator at the University of California Berkley’s Bakar BioEnginuity Hub, and given access to the Foundation’s unparalleled research infrastructure, including the ability to collaborate with the world's foremost experts in CF to advance their work.

The Foundation is committed to attracting new innovative companies into CF by de-risking early-stage science as part of its Path to a Cure initiative, which aims to accelerate treatments and drug development for the underlying cause of the disease, and ultimately deliver a cure for CF.

Companies at any stage of development are encouraged to apply for the Foundation’s industry funding opportunities.